Ligand Pharmaceuticals Incorporated
LGND
$159.76
$0.970.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 111.42% | -36.55% | -333.46% | 86.18% | -160.26% |
| Total Depreciation and Amortization | -2.58% | -3.69% | -4.08% | 1.59% | 1.00% |
| Total Amortization of Deferred Charges | -24.05% | -4.85% | 5.09% | 17.83% | 6.76% |
| Total Other Non-Cash Items | -35.47% | -65.90% | 43.55% | -57.59% | 174.59% |
| Change in Net Operating Assets | -19.41% | -144.54% | 62.93% | 193.57% | -192.32% |
| Cash from Operations | 162.09% | -189.37% | -22.06% | 174.37% | -28.92% |
| Capital Expenditure | 0.00% | 69.94% | -19.46% | -46.08% | -288.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -304.64% | 113.47% | 17.43% | 15.53% | -1,380.95% |
| Cash from Investing | -317.96% | 112.67% | 16.95% | 15.07% | -1,350.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -16.67% | 40.00% | -150.00% | 20.00% |
| Issuance of Common Stock | 95.14% | -92.52% | 163.97% | 123.98% | -37.58% |
| Repurchase of Common Stock | 98.37% | -359.48% | -1,448.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9,829.58% | 99.79% | -200.97% | 59,433.33% | -39.02% |
| Cash from Financing | 415.88% | -123.28% | -62.98% | 480.34% | -22.09% |
| Foreign Exchange rate Adjustments | 116.64% | 168.35% | -510.61% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -3,411.54% | -- | -- | -- | -- |
| Net Change in Cash | 180.93% | -379.90% | -80.90% | 242.33% | -217.74% |